< previous page page_xvii next page >

Page xvii
CONTRIBUTORS
Rebecca J. Anderson, Ph.D. R & D Budgets and Planning, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut
Umesh V. Banakar, Ph.D. Professor of Pharmaceutics and Director of Research, St. Louis College of Pharmacy, St. Louis, Missouri
Bret Berner, Ph.D. Executive Director of Development, Cygnus, Inc., Redwood City, California
Alan Bye, Ph.D. International Director, Glaxo-Wellcome Inc., Research Triangle Park, North Carolina
D. Bruce Campbell, Ph.D. Director of International Scientific Affairs, Servier Research and Development Ltd., Fulmer, Slough, England
Jim Cassidy, M.D., Ph.D. Professor of Oncology, University of Aberdeen, Aberdeen, Scotland
W.J.C. Currie, M.D. Executive Director, Clinical and Regulatory Development, Merck & Co., Inc., Rahway, New Jersey
Dai Davies, Ph.D. Clinical Pathology Laboratory, Zeneca Pharmaceuticals, Cheshire, England
Jan Gugliotti, M.B.A. CSC Index, Cambridge, Massachusetts

 
< previous page page_xvii next page >